<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Charlie King, Author at Pharmacy Update Online</title>
	<atom:link href="https://pharmacyupdateonline.com/author/charlieking/feed/" rel="self" type="application/rss+xml" />
	<link>https://pharmacyupdateonline.com/author/charlieking/</link>
	<description></description>
	<lastBuildDate>Thu, 19 Nov 2026 10:28:57 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.5</generator>

<image>
	<url>https://pharmacyupdateonline.com/wp-content/uploads/2020/12/cropped-favicon-512x360.png</url>
	<title>Charlie King, Author at Pharmacy Update Online</title>
	<link>https://pharmacyupdateonline.com/author/charlieking/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Daily iron supplements reduce iron deficiency anemia in children and adolescents</title>
		<link>https://pharmacyupdateonline.com/2026/11/daily-iron-supplements-reduce-iron-deficiency-anemia-in-children-and-adolescents/</link>
		
		<dc:creator><![CDATA[Charlie King]]></dc:creator>
		<pubDate>Sat, 21 Nov 2026 08:00:55 +0000</pubDate>
				<category><![CDATA[Medicines & Therapeutics]]></category>
		<category><![CDATA[Nutrition]]></category>
		<category><![CDATA[Paediatrics]]></category>
		<category><![CDATA[Practices & Services]]></category>
		<category><![CDATA[adolescents]]></category>
		<category><![CDATA[children]]></category>
		<category><![CDATA[Cochrane]]></category>
		<category><![CDATA[Cornell University]]></category>
		<category><![CDATA[iron deficiency anaemia]]></category>
		<category><![CDATA[iron supplementation]]></category>
		<guid isPermaLink="false">https://pharmacyupdateonline.com/?p=23278</guid>

					<description><![CDATA[<p>Giving children and adolescents a daily iron tablet significantly reduces the risk of iron deficiency anaemia with little to no effect on several common illnesses, according to a [&#8230;]</p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/11/daily-iron-supplements-reduce-iron-deficiency-anemia-in-children-and-adolescents/">Daily iron supplements reduce iron deficiency anemia in children and adolescents</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Giving children and adolescents a daily iron tablet significantly reduces the risk of iron deficiency anaemia with little to no effect on several common illnesses, according to a Cochrane review of 114 studies involving more than 50,000 participants.</p>
<p>Iron deficiency occurs when the body lacks enough iron for its needs. These include making haemoglobin, the protein in red blood cells that carries oxygen from the lungs to the rest of the body. Left untreated, it leads to iron deficiency anaemia.</p>
<p>Iron supplementation is the standard of care for the prevention and treatment of anaemia in many parts of the world particularly for adolescents and women. Previous evidence has pointed to the benefits of iron supplementation for improving iron deficiency anaemia in children. However, <a href="https://www.who.int/publications/i/item/9789241510196">current World Health Organization guidelines</a>, last updated in 2016, emphasize the gap in evidence on the long-term effects.</p>
<p>Led by researchers from Cornell Joan Klein Jacobs Center for Precision Nutrition and Health at Cornell University, the review included 114 studies with over 50,000 children and adolescents, looking at the effects of daily oral iron, alone or with folic acid or when other vitamins and minerals were added. Many of the studies were conducted in Asia and focused on children under five years of age.</p>
<p><strong>Daily iron reduces the risk of iron deficiency anaemia</strong></p>
<p>Findings from this review demonstrate that iron alone probably reduces iron deficiency anaemia compared with no intervention or placebo. Iron with folic acid probably reduces it too, although this finding rests on a single study, and iron with other vitamins and minerals also may reduce it. For anaemia and iron deficiency more broadly, there is some evidence that iron may be useful for reducing both.</p>
<p>Iron alone had no effect on how tall a child is or how much they weigh, compared with other children of the same age and sex. It also had no effect on several common illnesses, such as cough, fever or respiratory illness, and iron with folic acid makes little to no difference to diarrhoea or respiratory illness. Findings for other combinations ranged from moderate to very low certainty.</p>
<p>“Iron deficiency remains one of the most common nutritional problems affecting children worldwide,” says first author Dr Kripa Rajagopalan. “Our review shows that daily iron supplements do what they are meant to do, which is reduce iron deficiency anaemia, without any measurable impact on the common illnesses parents and health workers worry about.”</p>
<p><strong>Side effects are mostly mild, but evidence is uncertain</strong></p>
<p>The evidence on side effects was unclear for some outcomes. Iron may increase stool discolouration. Iron alone may make little to no difference to vomiting or diarrhoea, and the effect on constipation is very uncertain. Iron combined with other vitamins and minerals probably increases vomiting compared with the same supplement without iron.</p>
<p>Senior author Dr Saurabh Mehta explains: “While the evidence base supports the use of daily iron supplements where needed, some adverse effects do occur. Stool discolouration and, in some formulations, vomiting were more common with iron, and the certainty of evidence for several outcomes, including anaemia and iron deficiency themselves, was low or very low.”</p>
<p><strong>Anaemia remains a major global burden for young children</strong></p>
<p>Anaemia affects an estimated 874 million children and women worldwide; the greatest burden is seen among young children, with 40% of children younger than five years affected in 2019. Approximately half of these cases are due to iron deficiency. Reducing anaemia is a key goal of the <a href="https://www.who.int/publications/i/item/the-global-strategy-for-women-s-children-s-and-adolescents-health-(2016-2030)-early-childhood-development-report-by-the-director-general">2030 Global Strategy for Women’s, Children’s and Adolescents’ Health.</a></p>
<p>“These findings give decision-makers a stronger evidence base for guidance on iron supplementation in children and adolescents,” says co-author Dr Julia L. Finkelstein. “The data supports continued use of iron supplementation where iron deficiency is a concern.”</p>
<p>The authors stress that the findings support iron supplementation but should not be read as meaning every child or adolescent needs daily iron supplements. They should be interpreted in light of individual nutritional needs, the prevalence of iron deficiency and anaemia, and the formulation of the supplement.</p>
<div class="featured_image">
<div class="details">
<div class="well">
<h4>Journal</h4>
<p>Cochrane Database of Systematic Reviews</p>
</div>
<div class="well">
<h4>DOI</h4>
<p><a href="http://dx.doi.org/10.1002/14651858.CD013227.pub2" target="_blank" rel="noopener">10.1002/14651858.CD013227.pub2 <i class="fa fa-sign-out"></i></a></p>
</div>
<div class="well">
<h4>Method of Research</h4>
<p>Systematic review</p>
</div>
<div class="well">
<h4>Subject of Research</h4>
<p>People</p>
</div>
<div class="well">
<h4>Article Title</h4>
<p>Daily iron supplementation for prevention or treatment of iron-deficiency anaemia in infants, children, and adolescents</p>
</div>
<div class="well">
<h4>Article Publication Date</h4>
<p>16-Nov-2026</p>
</div>
<div class="well">
<h4>COI Statement</h4>
<p>Nabila Reem Khondakar: works as a Resident Physician at Northwestern Medicine and has no conflicts of interests to declare. Juan VA Franco: works as a Family Physician. Saurabh Mehta (SM): had an equity interest in a start-up commercialising point-of-care diagnostic technology for nutritional status developed in his laboratory as a faculty member at Cornell University. However, the company, Vitascan, was dissolved in May 2025 and the author received no financial payments. SM is also a principle investigator on competitive grants to conduct trials with iron-biofortified crops as an intervention to improve heal and related outcomes in children. Disclaimer: MNGC is a staff member of the World Health Organization (WHO). JPPR was a staff member of WHO. The authors alone are responsible for the views expressed in this publication, and they do not necessarily represent the decisions, policy or views of the World Health Organization. All other authors declare no conflicts of interest.</p>
</div>
</div>
</div>
<p>The post <a href="https://pharmacyupdateonline.com/2026/11/daily-iron-supplements-reduce-iron-deficiency-anemia-in-children-and-adolescents/">Daily iron supplements reduce iron deficiency anemia in children and adolescents</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Prescription by subscription: the hidden risks of online healthcare</title>
		<link>https://pharmacyupdateonline.com/2026/11/prescription-by-subscription-the-hidden-risks-of-online-healthcare/</link>
		
		<dc:creator><![CDATA[Charlie King]]></dc:creator>
		<pubDate>Fri, 20 Nov 2026 08:00:18 +0000</pubDate>
				<category><![CDATA[Legislative & Regulatory]]></category>
		<category><![CDATA[Practices & Services]]></category>
		<category><![CDATA[Service Developments]]></category>
		<category><![CDATA[Adelaide University]]></category>
		<category><![CDATA[Australia]]></category>
		<category><![CDATA[bioethics]]></category>
		<category><![CDATA[digital health]]></category>
		<category><![CDATA[online prescribing]]></category>
		<category><![CDATA[patient safety]]></category>
		<category><![CDATA[telehealth]]></category>
		<guid isPermaLink="false">https://pharmacyupdateonline.com/?p=23273</guid>

					<description><![CDATA[<p>Whether it’s a last-minute script, medical certificate or weight-loss treatment, many Australians are turning to online commercial health platforms for their healthcare. But while this model of care [&#8230;]</p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/11/prescription-by-subscription-the-hidden-risks-of-online-healthcare/">Prescription by subscription: the hidden risks of online healthcare</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Whether it’s a last-minute script, medical certificate or weight-loss treatment, many Australians are turning to online commercial health platforms for their healthcare. But while this model of care is quickly becoming big business, it also raises some significant ethical and policy issues, including risks to patient safety and consumer protection, according to new <a href="https://adelaide.edu.au/">Adelaide University</a> <a href="https://jmepb.bmj.com/content/2/4/e000189">research</a>.</p>
<p>Analysing the multi-billion-dollar online commercial health platform sector, bioethicists identified how online platforms are blurring the lines between patient and customer, potentially weakening patient care while increasing the risk of fragmented or inappropriate treatment.</p>
<p>They warn that because of the sector’s rapid evolution, regulation has struggled to keep pace, raising concerns about insufficient oversight, unsafe prescribing practices and the unethical influence of commercial interests on treatment decisions.</p>
<p>It’s a timely push, especially with the <a href="https://www.safetyandquality.gov.au/">Australian Commission on Safety and Quality in Health Care</a> announcing it has been tasked with developing <a href="https://www.safetyandquality.gov.au/news-and-media/media-release/national-standards-ensure-safe-high-quality-virtual-care-all-australians">national safety and quality standards for virtual care</a>.</p>
<p>In 2025, <a href="https://www.aihw.gov.au/reports/australias-health/digital-health">more than 11 million Australians had a telehealth consultation</a>, illustrating just how embedded virtual care and telehealth has become in Australia.</p>
<p>But these commercial online health platforms go well beyond the type of telehealth people might get from their local GP or public healthcare system and often sell questionable products and supplements alongside medications.</p>
<p>Generally sitting outside the traditional healthcare system, online-only services typically market themselves as one-stop shops for expensive private prescriptions – for example, weight loss injectables such as Wegovy or Mounjaro, hair loss medications, or even controversial peptide and testosterone treatments spruiked by influencers.</p>
<p>Lead researcher and bioethicist <a href="https://researchers.adelaide.edu.au/profile/hilary.bowman-smart">Dr Hilary Bowman-Smart</a> from Adelaide University’s <a href="https://adelaide.edu.au/research/australian-centre-for-precision-health/">Australian Centre for Precision Health</a> warns that while online commercial health platforms may provide convenient healthcare, they’re also creating risks.</p>
<p>“There’s no doubt commercial online health platforms are responding to a demand,” Dr Bowman-Smart said.</p>
<p>“These platforms can offer care that feels fast and convenient, especially with people facing increasingly long waits and rising costs for their healthcare. However, this doesn’t always mean it’s high-quality, appropriate or affordable care.</p>
<p>“Many of these platforms get people to sign up to ongoing subscriptions or memberships, similar to Netflix or Amazon Prime. That’s not what we think safe and ethical healthcare should be about.</p>
<p>“If people turn to these platforms because they don’t have or can’t get in to see a regular GP, this can create risks for people taking multiple medications or who have more complex healthcare needs.</p>
<p>“Our concern is that many people’s healthcare could become brief phone consults with a doctor they’ve never met before, or patients just filling out a form or clicking through an online quiz without details being double-checked or verified.</p>
<p>“Additionally, when people log on to a platform selling a specific ‘solution’, doctors can feel a lot of pressure to prescribe the solution that the patient wants or that the platform promotes, even if they don’t feel it’s right.</p>
<p>“There’s also the risk that important parts of a patient’s history or medical records get missed with short consults and the fact that many platforms don’t routinely use <a href="https://www.digitalhealth.gov.au/initiatives-and-programs/my-health-record">My Health Record</a>.</p>
<p>“This can harm patients – such as a patient with an eating disorder being prescribed a weight loss injectable – but it can also make doctors feel a loss of professional identity and values, and like they’re just reduced to ticking boxes. That’s bad for both sides of the equation.”</p>
<p>Conducted in partnership with the <a href="https://www.uow.edu.au/">University of Wollongong</a>, the team of bioethicists were also concerned about the growing influence of commercial interests on healthcare.</p>
<p><a href="https://scholars.uow.edu.au/patti-shih">Dr Patti Shih from the University of Wollongong</a> said with some platforms used familiar online shopping tactics such as product bundles and discount codes to sell prescription medicines alongside supplements and other wellness products.</p>
<p>“With this model of care, evidence-based treatments can be used as a type of ‘Trojan horse’ to sell people add-on wellness products and supplements,” Dr Shih said.</p>
<p>“For example, someone who is prescribed a hair loss medication may also be sold a ‘tailored’ plan with daily vitamins and shampoo products for ‘optimal results’, without those add-ons necessarily having the same medical evidence.”</p>
<p>With reports of <a href="https://www.abc.net.au/news/2026-01-28/national-medicines-register-in-honour-of-erin/106273618">overdosing</a>, <a href="https://www.abc.net.au/news/health/2026-08-31/telehealth-ozempic-wegovy-eating-disorder/107016932">inappropriate prescribing</a> and adverse health effects, researchers say national standards for the sector couldn’t come sooner.</p>
<p>“We know this sector is growing, but without good evidence and national standards, we risk profit coming at the expense of high-quality and appropriate care,” Dr Bowman-Smart said.</p>
<p>“People need to understand that these online commercial health platforms are very different from traditional healthcare.</p>
<p>“We hope the development of national standards and the upcoming introduction of a National Medicines Record will certainly go some way, but there’s still so much we don’t know about how this sector is operating and what further safeguards may be needed to protect patients.</p>
<p>“In the meantime, Australians need better information about when online care is appropriate, what to look out for and when they need more comprehensive care.”</p>
<p>The research team is now building on the findings through an <a href="https://audafoundation.org.au/">auDA Foundation</a>-funded project, working not only with the general public, but especially young Australians and people in regional, rural and remote communities to gain better understand their experiences of online healthcare.</p>
<p>The project will include community dialogue groups, a national survey and consultation with healthcare professionals, and will inform a plain-language <em>Health Online Toolkit</em> for consumers and an Action Paper for policymakers, professional bodies and advocates.</p>
<ul>
<li>The research article is accessible here: Bowman-Smart H, Shih P. <a href="https://doi.org/10.1136/jmepb-2026-000189">Prescription by subscription and the ethics of commercial digital health platforms</a>. <em>JME Practical Bioethics</em>. 2026;2:e000189.</li>
</ul>
<p>The post <a href="https://pharmacyupdateonline.com/2026/11/prescription-by-subscription-the-hidden-risks-of-online-healthcare/">Prescription by subscription: the hidden risks of online healthcare</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>One day in the ICU without care from a pharmacist increases death by 20%</title>
		<link>https://pharmacyupdateonline.com/2026/11/one-day-in-the-icu-without-care-from-a-pharmacist-increases-death-by-20/</link>
		
		<dc:creator><![CDATA[Charlie King]]></dc:creator>
		<pubDate>Thu, 19 Nov 2026 08:00:15 +0000</pubDate>
				<category><![CDATA[Emergency Medicine & Intensive Care]]></category>
		<category><![CDATA[Medicines & Therapeutics]]></category>
		<category><![CDATA[Pharmacology]]></category>
		<category><![CDATA[Practices & Services]]></category>
		<category><![CDATA[Service Developments]]></category>
		<category><![CDATA[CHEST Journal]]></category>
		<category><![CDATA[critical care pharmacists]]></category>
		<category><![CDATA[ICU]]></category>
		<category><![CDATA[medication safety]]></category>
		<category><![CDATA[patient mortality]]></category>
		<category><![CDATA[University of Georgia]]></category>
		<guid isPermaLink="false">https://pharmacyupdateonline.com/?p=23270</guid>

					<description><![CDATA[<p>Patients in intensive care units who don’t receive care from a pharmacist for even one day of their stay are 20% more likely to die, according to new [&#8230;]</p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/11/one-day-in-the-icu-without-care-from-a-pharmacist-increases-death-by-20/">One day in the ICU without care from a pharmacist increases death by 20%</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Patients in intensive care units who don’t receive care from a pharmacist for even one day of their stay are 20% more likely to die, according to <a href="https://journal.chestnet.org/article/S0012-3692(26)06717-6/fulltext">new research</a> led by the University of Georgia.</p>
<p>The study also found ICU patients were 10% more likely to die when pharmacists were responsible for more than 15 patients. For every one patient increase in a pharmacist’s workload, the odds of a patient dying increased by 1%.</p>
<p>“Critically ill patients experience an average of 1.7 medical errors per day, and nearly 80% of serious errors are caused by medications,” said <a href="https://rx.uga.edu/faculty-member/susan-e-smith/">Susan Smith</a>, lead author of the study and an associate professor in UGA’s <a href="https://rx.uga.edu/">College of Pharmacy</a>. Smith also practices critical care pharmacy in a local ICU.  “The comprehensive medication management provided by pharmacists is essential for ensuring medication safety.”</p>
<p>The researchers analyzed data from 213 pharmacists across 64 hospitals. The pharmacists provided information on their workload and every patient they cared for each day for 100 consecutive days, resulting in data from more than 28,000 patients. The researchers then compiled information on those patients’ severity of illness, health outcomes and more.</p>
<p>“Previous research has shown that having pharmacists present in ICUs is good and that it improves outcomes,” Smith said. “But this is the first publication to show that we need pharmacists in the ICU every day, seven days a week, 365 days a year.”</p>
<p><strong>Pharmacists guard against adverse drug events</strong></p>
<p>Critical care pharmacists are an integral part of the medical team in hospital ICUs. They review medications for potential drug interactions, optimize dosing and determine if a different medication would be a better fit.</p>
<p>Critical care pharmacists act as a key safeguard against adverse drug events, which kill an estimated 250,000 hospital patients each year.</p>
<p>“These findings could directly influence ICU care by reinforcing the importance of having critical care pharmacists involved in medication management every day of a patient’s ICU stay,” said Andrea Sikora, a senior author on the study and associate professor at the University of Colorado Anschutz. Sikora is also an adjunct associate professor in UGA’s College of Pharmacy. “The study also highlights the importance of evidence-based team design and the power of large-scale collaboration across institutions.”</p>
<p><strong>Hospital staffing, budgets may pose obstacle to patient care</strong></p>
<p>Most hospitals have critical care pharmacists in their ICUs. But about a third don’t, according to recent studies. And those that do are often limited to pharmacist presence on weekdays and day shift alone.</p>
<p>As hospital budgets shrink, having a critical care pharmacist on call 24/7 isn’t always a priority. But adding pharmacists to the team would likely save money in the long term through shorter patient stays and less reliance on costly life-sustaining measures, the researchers said.</p>
<p>“I’ve seen firsthand the consequences of both having and not having dedicated critical care pharmacists at the bedside,” said Mojdeh Heavner, a member of the study’s leadership team and a professor at the University of Maryland School of Pharmacy. Heavner is also an adjunct associate professor in the UGA College of Pharmacy. “These findings reinforce that pharmacist coverage in the ICU is not simply a staffing decision. It’s a patient safety and survival issue.</p>
<p>“We found a clear association between pharmacist workload and patient mortality. We hope these data will help hospital leaders advocate for the resources needed to ensure patients have access to critical care pharmacy expertise every day of their ICU stay.”</p>
<p>Published by CHEST Journal, the study was co-authored by Zhetao Chen and Xianyan Chen of the UGA College of Public Health. Additional co-authors include researchers from Wellstar MCG Health, Northeastern University, Brigham and Women’s Hospital, Emory University and the University of Colorado.</p>
<div class="featured_image">
<div class="details">
<div class="well">
<h4>Journal</h4>
<p>CHEST Journal</p>
</div>
<div class="well">
<h4>DOI</h4>
<p><a href="http://dx.doi.org/10.1016/j.chest.2026.09.027" target="_blank" rel="noopener">10.1016/j.chest.2026.09.027 <i class="fa fa-sign-out"></i></a></p>
</div>
<div class="well">
<h4>Article Title</h4>
<p>Optimization of Pharmacist Medication Management and Mortality in the ICU</p>
</div>
<div class="well">
<h4>Article Publication Date</h4>
<p>28-Sep-2026</p>
</div>
</div>
</div>
<p>The post <a href="https://pharmacyupdateonline.com/2026/11/one-day-in-the-icu-without-care-from-a-pharmacist-increases-death-by-20/">One day in the ICU without care from a pharmacist increases death by 20%</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>A new viewpoint argues exercise belongs on the prescription pad, not the advice pile, as a pillar of brain health care</title>
		<link>https://pharmacyupdateonline.com/2026/11/a-new-viewpoint-argues-exercise-belongs-on-the-prescription-pad-not-the-advice-pile-as-a-pillar-of-brain-health-care/</link>
		
		<dc:creator><![CDATA[Charlie King]]></dc:creator>
		<pubDate>Wed, 18 Nov 2026 08:00:29 +0000</pubDate>
				<category><![CDATA[Medicines & Therapeutics]]></category>
		<category><![CDATA[Mental Health]]></category>
		<category><![CDATA[Mind & Brain]]></category>
		<category><![CDATA[Neurology]]></category>
		<category><![CDATA[Psychiatry]]></category>
		<category><![CDATA[Sport & Exercise]]></category>
		<category><![CDATA[brain health]]></category>
		<category><![CDATA[dementia]]></category>
		<category><![CDATA[depression]]></category>
		<category><![CDATA[exercise prescription]]></category>
		<category><![CDATA[physical activity]]></category>
		<category><![CDATA[schizophrenia]]></category>
		<guid isPermaLink="false">https://pharmacyupdateonline.com/?p=23266</guid>

					<description><![CDATA[<p>Most of us have heard the advice so often that it has worn smooth, like a stone in a river: get some exercise. A new peer-reviewed Viewpoint in [&#8230;]</p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/11/a-new-viewpoint-argues-exercise-belongs-on-the-prescription-pad-not-the-advice-pile-as-a-pillar-of-brain-health-care/">A new viewpoint argues exercise belongs on the prescription pad, not the advice pile, as a pillar of brain health care</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Most of us have heard the advice so often that it has worn smooth, like a stone in a river: get some exercise. A new peer-reviewed Viewpoint in Brain Health, drawing on randomized trials, meta-analyses, and cohort studies, argues that this familiar sentence has been doing the wrong job. Exercise, the authors contend, is not a suggestion to be tossed off at the end of an appointment. It is a treatment. It deserves to be prescribed like one.</p>
<p>The piece comes from Carl Zhou, MD, and Nicholas Fabiano, MD, of the Department of Psychiatry at the University of Ottawa, and Stanley Wong, MD, of the Department of Psychiatry at the University of Toronto. Brain health, they write, means sustaining cognitive, emotional, behavioral, and social functioning across the life course, and exercise touches nearly every one of those domains. Why, then, does clinical practice so often file it under lifestyle chatter?</p>
<p><strong>What moves when the muscles move</strong></p>
<p>What, exactly, happens inside the skull when the legs start working? Brain function, the authors note, depends on sound blood vessels, balanced metabolism, controlled inflammation, and neuroplasticity, and exercise reaches into each. One useful map is the muscle-brain axis: contracting skeletal muscle releases signaling molecules called myokines, which interact with metabolic, inflammatory, neuroendocrine, and neurotrophic pathways tied to mood and cognition. It is one model among several; sleep, vascular risk, and the psychology of mastery and connection matter too.</p>
<p>The historical anchor is a randomized trial in older adults, published in 2011 by Erickson and colleagues, in which aerobic exercise increased the volume of the anterior hippocampus, a region central to memory, and improved memory itself. The Viewpoint adds the caveat a careful reader wants: some of the broader evidence linking activity to sharper cognition and slower brain aging is observational, and should be read that way.</p>
<p>“We still tend to treat exercise as general lifestyle advice,” said Dr. Zhou, the corresponding author. “The evidence we reviewed supports something more deliberate: a prescription that names the type of activity, the frequency, the intensity, the duration, the safety considerations, and a plan for follow-up, just as we would for a medication.”</p>
<p><strong>Where the evidence runs strong, and where it thins</strong></p>
<p>On mood, the synthesis speaks with the most confidence. Across diverse populations, randomized and meta-analytic evidence indicates that physical activity interventions can reduce depressive symptoms, anxiety, psychological distress, and suicide-related outcomes. A 2024 network meta-analysis of randomized trials found that walking, jogging, yoga, and strength training reduced symptoms of depression, with larger effects generally seen at higher intensity.</p>
<p>Then a detail patients may find unexpectedly kind: dose-response analyses suggest that the benefit appears below guideline targets, at roughly half the recommended public-health volume, about 75 minutes a week of moderate activity. For someone who cannot picture the full goal, that is a door left ajar. Could a modest dose that a person actually sustains matter more than an ambitious one that never begins?</p>
<p>For the aging brain, physical activity has been associated with lower risk of cognitive impairment, all-cause dementia, and Alzheimer’s disease, and the World Health Organization includes physical activity in its recommendations for reducing dementia risk. Observational designs, the authors stress, limit causal interpretation.</p>
<p><strong>A neglected population, and a pharmacological question</strong></p>
<p>The Viewpoint gives particular attention to people with schizophrenia and other severe mental illness, who carry high rates of sedentary behavior, cardiometabolic disease, and premature mortality, driven partly by social disadvantage and medication side effects. Meta-analytic evidence suggests that aerobic exercise may improve global cognition in schizophrenia, with possible benefits in working memory, attention, and social cognition. That matters, because cognitive impairment strongly shapes functional outcome and most available drugs do little for it.</p>
<p>“In schizophrenia, exercise can work on psychiatric symptoms, cognition, and physical health at the same time, in a population with substantial unmet needs in all three,” said Dr. Wong. “But the cognition findings rest on a limited set of modest trials, and adequately powered studies are what the field needs next.”</p>
<p>And what of patients who cannot move enough? The muscle-brain model has stirred interest in exercise mimetics, agents that may theoretically reproduce some molecular effects of exercise. The authors draw a firm line: such agents would be an adjunct for people facing major barriers to movement, not a substitute for safe, accessible activity.</p>
<p><strong>Writing the prescription</strong></p>
<p>The World Health Organization recommends 150 to 300 minutes of moderate-intensity aerobic activity per week for adults, or 75 to 150 minutes of vigorous activity, plus muscle strengthening on at least two days. Safety is addressed head on: frailty, unstable cardiac or respiratory symptoms, or recent falls may call for medical assessment, supervision, or a temporary pause. For most patients, the authors favor a graded path, starting low and progressing gradually.</p>
<p>Because depression drains energy and motivation, the first step may be small: a five-minute walk, chair-based exercise, a supervised group, or an activity already woven into the day, such as walking the dog.</p>
<p>“The starting point does not have to be impressive. It has to be possible,” said Dr. Fabiano. “Small, repeated successes build self-efficacy and habit, and that is what creates the conditions for sustained activity.”</p>
<p><strong>Access is part of the dose</strong></p>
<p>The closing argument concerns fairness. Clinicians can screen for activity at routine visits, coordinate with primary care and physiotherapy, and connect patients to community programs. Yet prescribing exercise without addressing access, the authors warn, can widen inequities. Their remedies are concrete: funded community exercise programs, transportation support, and partnerships with recreation and community centers. Who can follow a prescription that they have no way to fill?</p>
<p>The Viewpoint is candid that evidence strength differs across outcomes and study designs. Exercise can be scalable and low cost when access barriers are addressed, and it improves energy, function, sleep, and quality of life. The task, as the authors frame it, is to help each patient find movement that is safe, meaningful, and sustainable. The old advice was never wrong. It was simply unfinished.</p>
<p>The peer-reviewed Viewpoint in Brain Health titled “Exercise is critical for brain health,” is freely available via Open Access, starting on 3 November 2026 in Brain Health at the following hyperlink: <a href="https://doi.org/10.61373/bh026v.0027">https://doi.org/10.61373/bh026v.0027</a>.</p>
<p>The full reference for citation purposes is: Zhou C, Wong S, Fabiano N. Exercise is critical for brain health. Brain Health 2026. DOI: <a href="https://doi.org/10.61373/bh026v.0027">https://doi.org/10.61373/bh026v.0027</a>. Epub 2026 Nov 3.</p>
<p><strong>About Brain Health: </strong>Brain Health (ISSN: 3142-9963, online and 3142-9947, print) is a peer-reviewed medical research journal published by Genomic Press, New York, dedicated to the science of lifelong brain resilience. The journal’s scope spans molecular and cellular neuroscience, neuroimaging, electrophysiology, computational modeling, clinical trials, epidemiology, digital health, behavioral intervention science, psychology, normative data, and the social sciences and humanities, organized around the question of how human brains remain resilient, recover when injured, and stay functional across the longest possible arc of a life. Brain Health operates alongside its sister journal Brain Medicine, with the two journals together covering the continuum from disease to resilience.</p>
<p>Visit the Genomic Press Virtual Library: <a href="https://issues.genomicpress.com/bookcase/gtvov/">https://issues.genomicpress.com/bookcase/gtvov/</a></p>
<p>Our media website is at: <a href="https://media.genomicpress.com/">https://media.genomicpress.com/</a></p>
<p>Our full website is at: <a href="https://genomicpress.com/">https://genomicpress.com/</a></p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/11/a-new-viewpoint-argues-exercise-belongs-on-the-prescription-pad-not-the-advice-pile-as-a-pillar-of-brain-health-care/">A new viewpoint argues exercise belongs on the prescription pad, not the advice pile, as a pillar of brain health care</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Patient comfort with AI-driven healthcare hinges on provider oversight</title>
		<link>https://pharmacyupdateonline.com/2026/11/patient-comfort-with-ai-driven-healthcare-hinges-on-provider-oversight/</link>
		
		<dc:creator><![CDATA[Charlie King]]></dc:creator>
		<pubDate>Tue, 17 Nov 2026 08:00:43 +0000</pubDate>
				<category><![CDATA[Artificial intelligence]]></category>
		<category><![CDATA[Devices & Technology]]></category>
		<category><![CDATA[Practices & Services]]></category>
		<category><![CDATA[Primary Care]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[AI training]]></category>
		<category><![CDATA[clinical decision-making]]></category>
		<category><![CDATA[Gallup]]></category>
		<category><![CDATA[Patient survey]]></category>
		<category><![CDATA[West Health]]></category>
		<guid isPermaLink="false">https://pharmacyupdateonline.com/?p=23188</guid>

					<description><![CDATA[<p>More than half of patients (56%) are comfortable with artificial intelligence (AI) making diagnosis or treatment decisions when their healthcare provider can change or override them, but that [&#8230;]</p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/11/patient-comfort-with-ai-driven-healthcare-hinges-on-provider-oversight/">Patient comfort with AI-driven healthcare hinges on provider oversight</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>More than half of patients (56%) are comfortable with artificial intelligence (AI) making diagnosis or treatment decisions when their healthcare provider can change or override them, but that figure falls to just 9% when AI makes those decisions without provider review, according to <a href="https://news.gallup.com/poll/716261/patient-comfort-depends-provider-involvement.aspx">new data</a> from the West Health-Gallup Center on Healthcare in America. The nationally representative survey of more than 5,000 U.S. adults found similar patterns in patient comfort with AI used to interpret diagnostic images or make medication decisions.</p>
<p>In a separate survey of more than 1,000 healthcare providers, nearly nine in 10 (89%) report using AI for work in the past year, but only 20% report receiving any formal AI training. Training rates varied considerably by practice setting, from 30% of providers in hospitals or health-systems practices to 16% in provider groups and just 11% in independent practices.</p>
<p>The survey also revealed providers underestimate how comfortable their patients are with AI. When AI makes diagnosis and treatment decisions that a provider can override, 56% of patients say they would be comfortable, but only 36% of providers believe most of their patients would be, a 20-percentage-point gap. That comfort collapses when the provider is removed, with just 9% saying they would be comfortable with AI making diagnosis and treatment decisions without provider review.</p>
<p>“AI has enormous potential to improve healthcare, but patients are sending a clear message that they are not afraid of using the technology, and want their providers involved, not replaced,” said Timothy Lash, President and Chair of the West Health Policy Center in Washington, D.C. “This makes it critical that providers have the training to use it effectively and patients have trust in how AI is being used to guide medical decisions.”</p>
<p><strong>Provider Oversight, Not Replacement, Drives Patient Comfort</strong></p>
<p>Patients were asked about their comfort with AI in three areas of clinical care — diagnosis and treatment, imaging review, and medication decisions — under three levels of provider involvement:</p>
<ul>
<li><strong>AI assists:</strong> AI provides recommendations, but the healthcare provider makes the final decision.</li>
<li><strong>AI decides, with provider oversight:</strong> Provider can change or override AI decisions.</li>
<li><strong>AI decides independently:</strong> AI makes the decision without provider review.</li>
</ul>
<p>About half of patients say they are comfortable when AI makes decisions subject to a provider override (53% for imaging and 49% for medications) or when AI assists and the provider decides (52% and 45%, respectively). Without provider review, comfort drops to 13% for reviewing diagnostic images and 11% for medication decisions.</p>
<p>The preference for provider engagement extends even among patients most receptive to AI for healthcare. Of the 39% of patients who have used AI to gather physical or mental health information or advice in the past year, over half are comfortable with AI assisting their provider, but only 12% to 16% are comfortable with clinical advice from AI without that assistance. Similarly, among the 23% of patients who trust AI-generated health information, 65% to 71% say they are comfortable with its use in clinical care when a provider provides oversight, compared with just 18% to 20% who are comfortable without provider review.</p>
<p><strong>AI Use Outpaces Training as Providers Gauge Patient Comfort</strong></p>
<p>AI is already routinely used in primary care, mostly for gathering information about medications (78%) or symptoms and conditions (76%). More than half (53%) have used it to review patient-specific information, such as test results or imaging, while 50% have used it to write clinical notes. Nearly half have used AI to prepare patient instructions or after-visit summaries (49%), summarize or retrieve information from medical records (47%), or record and transcribe patient appointments (45%).</p>
<p>“These findings suggest reason for optimism about the role of AI in healthcare,” said Joe Daly, Global Managing Partner at Gallup. “The data show that patients are open to AI having a role in their care, particularly when they know a clinician can still step in. As AI becomes more integrated into healthcare, understanding where patients are comfortable with its use versus where they still value human oversight will be critical.”</p>
<p><strong>Methodology</strong></p>
<p>For results from patients: Results are based on a Gallup Panel<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> study conducted Aug. 12-24, 2026, with 5,330 U.S. adults, aged 18 and older, who are members of the Gallup Panel. Gallup uses probability-based, random sampling methods to recruit its Panel members.</p>
<p>For results based on the total sample, the margin of sampling error is ±1.7 percentage points at the 95% confidence level.</p>
<p>For results from providers: Results are based on a non-probability opt-in panel study conducted Aug. 7-23, 2026, with 1,007 U.S. adults, aged 18 and older. All surveys were conducted as web surveys and in English. Respondents without internet access were not covered by this study.</p>
<p>For results based on the total sample, the credibility interval is ±3.3 percentage points at the 95% confidence level.</p>
<p><strong> </strong><strong>About the West Health-Gallup Center on Healthcare in America</strong></p>
<p>The Center on Healthcare in America is a joint initiative from West Health and Gallup dedicated to elevating the voices and experiences of Americans within the healthcare system. Through rigorous research and human-centered storytelling, the Center aims to drive actionable insights and inform policy solutions nationwide. Visit <a href="http://www.westhealth.gallup.com/" target="_blank" rel="noopener">www.westhealth.gallup.com</a>.</p>
<p><strong> </strong><strong>About West Health</strong></p>
<p>Solely funded by philanthropists Gary and Mary West, <a href="https://www.westhealth.org/" target="_blank" rel="noopener">West Health </a>is a family of nonprofit and nonpartisan organizations that include the <a href="https://www.westhealth.org/what-we-do/outcomes-based-philanthropy/" target="_blank" rel="noopener">Gary and Mary West Foundation</a> and <a href="https://www.westhealth.org/what-we-do/research/" target="_blank" rel="noopener">Gary and Mary West Health Institute</a> in San Diego and the <a href="https://www.westhealth.org/what-we-do/policy-advocacy-2/" target="_blank" rel="noopener">Gary and Mary West Health Policy Center</a> in Washington, D.C. West Health is dedicated to <a href="https://www.westhealth.org/lowering-healthcare-costs/" target="_blank" rel="noopener">lowering healthcare costs</a> to enable seniors to <a href="https://www.westhealth.org/who-we-are/successful-aging/" target="_blank" rel="noopener">successfully age</a> in place with access to high-quality and affordable health and support services that preserve and protect their dignity, quality of life and independence. Learn more at <a href="https://www.westhealth.org/" target="_blank" rel="noopener">westhealth.org</a>.</p>
<p><strong> </strong><strong>About Gallup</strong></p>
<p>Gallup delivers analytics and advice to help leaders and organizations solve their most pressing problems. Combining 90 years of experience with its global reach, Gallup knows more about the attitudes and behaviors of employees, customers, students and citizens than any other organization in the world.</p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/11/patient-comfort-with-ai-driven-healthcare-hinges-on-provider-oversight/">Patient comfort with AI-driven healthcare hinges on provider oversight</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>People worry most about hormone-disrupting chemicals in food and drink, least in skin products, study finds</title>
		<link>https://pharmacyupdateonline.com/2026/11/people-worry-most-about-hormone-disrupting-chemicals-in-food-and-drink-least-in-skin-products-study-finds/</link>
		
		<dc:creator><![CDATA[Charlie King]]></dc:creator>
		<pubDate>Mon, 16 Nov 2026 08:00:16 +0000</pubDate>
				<category><![CDATA[Diabetes & Endocrinology]]></category>
		<category><![CDATA[Environmental Health]]></category>
		<category><![CDATA[Medicines & Therapeutics]]></category>
		<category><![CDATA[Practices & Services]]></category>
		<category><![CDATA[Aarhus University]]></category>
		<category><![CDATA[EDCs]]></category>
		<category><![CDATA[endocrine-disrupting chemicals]]></category>
		<category><![CDATA[public health]]></category>
		<category><![CDATA[Risk Analysis]]></category>
		<category><![CDATA[risk perception]]></category>
		<guid isPermaLink="false">https://pharmacyupdateonline.com/?p=23185</guid>

					<description><![CDATA[<p>When it comes to hormone-disrupting chemicals, people worry most about what they eat and drink and least about what they put on their skin, according to new research [&#8230;]</p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/11/people-worry-most-about-hormone-disrupting-chemicals-in-food-and-drink-least-in-skin-products-study-finds/">People worry most about hormone-disrupting chemicals in food and drink, least in skin products, study finds</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>When it comes to hormone-disrupting chemicals, people worry most about what they eat and drink and least about what they put on their skin, according to new research published in <em>Risk Analysis. </em></p>
<p>The survey of adults in Denmark, the United Kingdom and the United States found that people judge the risks of these endocrine-disrupting chemicals (EDCs) less by the chemical itself than by how it gets into the body. People who said they knew more about EDCs also believed they were more vulnerable to them &#8212; a sign that giving people more information may not, on its own, put their minds at ease.</p>
<p>EDCs are substances that interfere with the body’s hormonal signaling and are associated with adverse health effects, including harm to reproductive health, metabolism and increased cancer risk. People are exposed to EDCs in several ways: pesticides in food and water, personal care products on the skin and household dust carrying chemicals from furniture, electronics and building materials. While scientists broadly agree that many EDCs are hazardous, little is known about how the public turns that information into judgments about their risks. Earlier studies looked at single settings, such as food or household products, rather than comparing exposure routes across countries.</p>
<p>Researchers from Aarhus University and the Swedish University of Agricultural Sciences surveyed 1,966 adults: 657 in Denmark, 657 in the U.K. and 652 in the U.S. Participants rated 18 everyday scenarios, such as drinking from plastic bottles containing BPA, applying sunscreen containing parabens and breathing air containing phthalates from indoor air fresheners. They scored each scenario on factors such as dread, controllability and how well the risk is understood, ranked for perceived health risk and answered questions about EDC health risks, institutional trust and their knowledge of EDCs.</p>
<p><strong>Key Findings </strong></p>
<ul>
<li>Perceptions tracked the route of exposure, not the chemical. In all three countries, people rated eating and drinking as riskiest, followed by breathing and lastly by skin products. Scenarios clustered by how individuals were exposed, rather than by the chemical itself.</li>
</ul>
<ul>
<li>People see EDCs as slow-building hazards that science understands well. Participants expected harm to show up over time rather than right away and rated feelings of dread, chronic harm and fatality near the middle of the scale. Breathing in chemicals felt involuntary and hard to control, while skin products seemed familiar and manageable.</li>
</ul>
<ul>
<li>Knowing more went hand in hand with worrying more. In all three countries, people who said they knew more about EDCs rated their likelihood of becoming ill from them more highly. Women in the U.S. and U.K. reported a higher perceived likelihood of becoming ill from EDCs and greater perceived overall health risk than men did. Other demographic patterns varied by country.</li>
</ul>
<ul>
<li>Trust cut different ways in different countries. In the U.S. and U.K., people with more institutional trust saw the likelihood of becoming ill from EDCs as higher. In Denmark, more trust was linked to lower perceived overall health risk.</li>
</ul>
<ul>
<li>Americans and Britons reacted more emotionally; Danes more deliberately. Across countries, judgments reflected two sets of factors: emotional ones, such as dread, fatality and catastrophic potential, and deliberative ones, such as knowledge and controllability. U.S. and U.K. participants leaned more on the emotional factors, while Danish participants gave more weight to the deliberative ones.</li>
</ul>
<p>&#8220;Our findings suggest that health agencies should think less about communicating individual chemicals and more about how people get exposed,&#8221; said Nick Simonsen, lead author and researcher at Aarhus University. &#8220;People make sense of these risks through everyday activities like eating, drinking, breathing indoor air and using personal care products. Framing information around those experiences, with concrete steps people can take to reduce risks, may help make public health messages more relevant and actionable.&#8221;</p>
<p>The authors also recommend tailoring outreach to audiences’ knowledge and trust rather than to broad demographic groups, and adapting multinational campaigns to national differences.</p>
<p>The authors note that the survey captured a single point in time and relied on what participants reported about themselves, so it cannot establish cause and effect. Participants received an introduction to EDCs before answering, and the study did not measure behavior or actual chemical exposure.</p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/11/people-worry-most-about-hormone-disrupting-chemicals-in-food-and-drink-least-in-skin-products-study-finds/">People worry most about hormone-disrupting chemicals in food and drink, least in skin products, study finds</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>To quit smoking, what methods work best in the real world?</title>
		<link>https://pharmacyupdateonline.com/2026/11/to-quit-smoking-what-methods-work-best-in-the-real-world/</link>
		
		<dc:creator><![CDATA[Charlie King]]></dc:creator>
		<pubDate>Sun, 15 Nov 2026 08:00:27 +0000</pubDate>
				<category><![CDATA[Addiction]]></category>
		<category><![CDATA[Mind & Brain]]></category>
		<category><![CDATA[Pharmacology]]></category>
		<category><![CDATA[Practices & Services]]></category>
		<category><![CDATA[addiction]]></category>
		<category><![CDATA[E-cigarettes]]></category>
		<category><![CDATA[National Cancer Institute]]></category>
		<category><![CDATA[nicotine replacement therapy]]></category>
		<category><![CDATA[smoking]]></category>
		<category><![CDATA[smoking cessation]]></category>
		<category><![CDATA[USC Institute for Addiction Science]]></category>
		<guid isPermaLink="false">https://pharmacyupdateonline.com/?p=23182</guid>

					<description><![CDATA[<p>An upcoming study of thousands of Americans aims to measure how effectively U.S. Food and Drug Administration-approved medications, including nicotine patches and prescription pills, help people quit smoking [&#8230;]</p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/11/to-quit-smoking-what-methods-work-best-in-the-real-world/">To quit smoking, what methods work best in the real world?</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>An upcoming study of thousands of Americans aims to measure how effectively U.S. Food and Drug Administration-approved medications, including nicotine patches and prescription pills, help people quit smoking while living their normal lives.</p>
<p>FDA-approved medicines appear to successfully help people quit smoking when used in tightly controlled clinical trials in medical centers, but naturalistic studies of the medications produce mixed results. Many observational studies find they are roughly as effective as going “cold turkey” and quitting without aid, said <a href="https://ias.usc.edu/adam-m-leventhal-phd/">Adam Leventhal</a>, director of the USC Institute for Addiction Science.</p>
<p>The study is a collaboration between USC and the University of Nebraska and is funded by a grant of $4.7 million over five years from the National Cancer Institute. The new methodology will combine intensive research assessment with real-world conditions in a nationally representative study to definitively determine how effective FDA-approved aids for smoking cessation are for people living their everyday lives. The study will also collect data to discover if various non-FDA-approved products that smokers use actually work and assist quitting, said Leventhal, who is a co-principal investigator on the grant with <a href="https://www.unmc.edu/publichealth/departments/biostatistics/facultyandstaff/hongying-dai.html">Hongying “Daisy” Dai</a> of the University of Nebraska Medical Center.</p>
<p><strong>Many Americans want to quit but face long odds</strong></p>
<p>As of 2025, approximately <a href="https://nchsdata.cdc.gov/dqs/?topic=current-cigarette-smoking&amp;topic_id=110190&amp;subtopic=&amp;group=&amp;subgroup=&amp;range=&amp;estimate=&amp;subtopic_id=610330">9.2% of American adults</a> smoke cigarettes, according to the Centers for Disease Control and Prevention. The adult smoking rate peaked at 42.4% in 1965 following a landmark U.S. Surgeon General’s report on the health risks of smoking.</p>
<p>Each year, about 75% of all smokers in the United States say they want to kick the habit. About half of them attempt to quit, but only 8% manage to successfully stop smoking, Leventhal said. These statistics have been the same for more than a decade, he added, noting that many of individuals who manage to quit smoking for a period of time still eventually relapse.</p>
<p>“While fewer people in the U.S. smoke each year, the reason is not because more people are quitting smoking; it is because fewer young people are picking up smoking each year due to education regarding tobacco risks and policies that restrict tobacco use, sales and marketing,” he said.</p>
<p>To help improve American smokers’ low chances of quitting for good, Leventhal and Dai have assembled a robust, interdisciplinary team, Leventhal said. USC Institute for Addiction Science experts have partnered with University of Nebraska Medical Center quantitative scientists to analyze new data that will be obtained by the USC Center for Economic and Social Research (CESR) <a href="https://uasdata.usc.edu/index.php">Understanding America Study</a>.</p>
<p>“Our collaboration between USC and UNMC brings together complementary expertise in addiction science and advanced modeling,” Dai said. “We will also integrate rich auxiliary data to examine how policy and environmental factors influence cessation aid uptake and smoking outcomes.”</p>
<p>The study enables researchers to survey thousands of U.S. adults who smoke and track individuals who make quit-smoking attempts “with more detail and precision than ever before,” Leventhal said.</p>
<p>“We will track what happens before the quit attempt, what quit-smoking aids they use and what happens after the quit attempt up to four years later,” he said. “This will allow us to determine which FDA-approved medications, as well as non-FDA-approved methods such as e-cigarettes and CBD, help people get motivated to quit and keep them smoke-free for years without relapsing.”</p>
<p><strong>Immediate impact for improving lives</strong></p>
<p>The need for better information on how people can quit smoking is huge for public health. Smoking remains the leading cause of preventable death in the United States and accounts for more costs to the healthcare system than nearly every other modifiable health behavior, Leventhal said.</p>
<p>“Due to persistently low smoking cessation rates in the U.S., it is important to provide new evidence that will compel healthcare professionals and insurance plans to encourage their patients to use evidence-based smoking cessation methods,” he said.</p>
<p>Leventhal said he hopes the data collected during the new study will help determine which FDA-approved medications are most effective for helping people quit tobacco and increase the rate at which Americans give up smoking. He also is looking forward to learning whether nonmedicinal methods anecdotally used to support quitting, such as e-cigarette vaping or taking cannabis-based products with THC or CBD, actually help people during the quitting process.</p>
<p>“Ideally, our findings will help doctors, nurses, psychologists, social workers and other clinicians have the knowledge of which smoking cessation aids to recommend to their patients,” he said. “Also, I hope more policymakers will introduce legislation to mandate coverage of quit-smoking aids that show real-world effectiveness in our study. If more healthcare plans cover smoking cessation aids, they can help their customers and patients stay smoke-free for good.”</p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/11/to-quit-smoking-what-methods-work-best-in-the-real-world/">To quit smoking, what methods work best in the real world?</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Excessive polypharmacy and complex medication regimens are associated with greater physician burden in home healthcare</title>
		<link>https://pharmacyupdateonline.com/2026/11/excessive-polypharmacy-and-complex-medication-regimens-are-associated-with-greater-physician-burden-in-home-healthcare/</link>
		
		<dc:creator><![CDATA[Charlie King]]></dc:creator>
		<pubDate>Sat, 14 Nov 2026 08:00:59 +0000</pubDate>
				<category><![CDATA[Elderly Care]]></category>
		<category><![CDATA[Pharmacology]]></category>
		<category><![CDATA[Practices & Services]]></category>
		<category><![CDATA[Primary Care]]></category>
		<category><![CDATA[Family Practice]]></category>
		<category><![CDATA[home healthcare]]></category>
		<category><![CDATA[medication regimen complexity]]></category>
		<category><![CDATA[Older Adults]]></category>
		<category><![CDATA[physician burden]]></category>
		<category><![CDATA[polypharmacy]]></category>
		<guid isPermaLink="false">https://pharmacyupdateonline.com/?p=23178</guid>

					<description><![CDATA[<p>Patients receiving home-based medical care are often older adults with multiple chronic conditions, and polypharmacy, commonly defined as the concurrent use of multiple medications, is prevalent in this [&#8230;]</p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/11/excessive-polypharmacy-and-complex-medication-regimens-are-associated-with-greater-physician-burden-in-home-healthcare/">Excessive polypharmacy and complex medication regimens are associated with greater physician burden in home healthcare</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Patients receiving home-based medical care are often older adults with multiple chronic conditions, and polypharmacy, commonly defined as the concurrent use of multiple medications, is prevalent in this population. However, the challenges of medication management extend beyond the number of prescribed medications. Factors such as dosing frequency, dosage forms, and special administration requirements can make medication regimens more difficult to manage for both patients and healthcare professionals. Although polypharmacy and complex medication regimens have been associated with increased treatment burden and medication-related problems, their relationship with the perceived clinical burden of physicians providing home healthcare has remained unclear.</p>
<p>To address this knowledge gap, researchers examined 503 patients receiving home-based medical care at seven medical institutions in Tokyo and Ibaraki Prefecture, Japan. The research team assessed both the number of prescribed medications and the complexity of medication regimens and investigated their associations with physicians&#8217; perceived clinical burden. The results showed that physicians experienced a significantly greater burden when caring for patients with excessive polypharmacy, defined as the use of 10 or more medications, and those with particularly complex medication regimens. These associations remained significant after adjustment for factors including patient age, comorbidities, and consultation time.</p>
<p>The findings suggest that improving medication management in home healthcare requires attention not only to reducing unnecessary medications but also to simplifying medication regimens whenever clinically appropriate. The researchers also highlighted the potential benefits of multidisciplinary collaboration, particularly between physicians and pharmacists, in optimizing pharmacotherapy, reducing physician burden, and ensuring safe and effective treatment for patients receiving home-based care. As healthcare systems continue to expand community- and home-based services to meet the needs of aging populations, strategies that support both patients and healthcare professionals will become increasingly important.</p>
<p>This work was supported by the Japan Society for the Promotion of Science, 21K15658.</p>
<p>Title of original paper:<br />
Excessive Polypharmacy and Complicated Medication Regimen are associated with Physicians&#8217; Perceived Burden in Home Healthcare: A Multicenter Cross-Sectional Study</p>
<p>Journal:<br />
<em>Family Practice</em></p>
<p>DOI:<br />
<a href="https://doi.org/10.1093/fampra/cmag079" target="_blank" rel="noopener">10.1093/fampra/cmag079</a></p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/11/excessive-polypharmacy-and-complex-medication-regimens-are-associated-with-greater-physician-burden-in-home-healthcare/">Excessive polypharmacy and complex medication regimens are associated with greater physician burden in home healthcare</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Doxycycline use in early pregnancy associated with higher risk of pregnancy loss</title>
		<link>https://pharmacyupdateonline.com/2026/11/doxycycline-use-in-early-pregnancy-associated-with-higher-risk-of-pregnancy-loss/</link>
		
		<dc:creator><![CDATA[Charlie King]]></dc:creator>
		<pubDate>Fri, 13 Nov 2026 08:00:34 +0000</pubDate>
				<category><![CDATA[Medicines & Therapeutics]]></category>
		<category><![CDATA[Obstetrics & Gynaecology]]></category>
		<category><![CDATA[Pharmacology]]></category>
		<category><![CDATA[Practices & Services]]></category>
		<category><![CDATA[Annals of Internal Medicine]]></category>
		<category><![CDATA[Antibiotics]]></category>
		<category><![CDATA[Doxycycline]]></category>
		<category><![CDATA[drug]]></category>
		<category><![CDATA[pregnancy]]></category>
		<category><![CDATA[pregnancy loss]]></category>
		<guid isPermaLink="false">https://pharmacyupdateonline.com/?p=23175</guid>

					<description><![CDATA[<p>A retrospective, active-comparator cohort study found that doxycycline use for respiratory tract infections or acne during early pregnancy was associated with an increased risk for pregnancy loss. Given [&#8230;]</p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/11/doxycycline-use-in-early-pregnancy-associated-with-higher-risk-of-pregnancy-loss/">Doxycycline use in early pregnancy associated with higher risk of pregnancy loss</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>A retrospective, active-comparator cohort study found that doxycycline use for respiratory tract infections or acne during early pregnancy was associated with an increased risk for pregnancy loss. Given the frequent use of doxycycline by women of childbearing age, these findings underscore the importance of both clinicians and patients weighing the benefits and risks when considering treatment with doxycycline. The findings are published in <em>Annals of Internal Medicine</em>.</p>
<p>Doxycycline is a commonly used antibiotic that is prescribed to treat a variety of infections, including skin and respiratory tract infections. Researchers from the University of Florida and colleagues analyzed insurance claims data from commercial and Medicaid databases of 218,234 pregnancies from women with respiratory tract infections and 6,636 pregnancies from women with acne to assess whether taking doxycycline during early pregnancy was associated with pregnancy loss. They compared women who filled prescriptions for doxycycline during the first trimester with similar women who received alternative treatments, including amoxicillin and macrolide for respiratory tract infections and topical clindamycin for acne. In both insurance claims databases, there was a higher risk for pregnancy loss among women with respiratory tract infections who used doxycycline. In patients with acne, risk was higher in pregnancies with doxycycline exposure in the commercial claims database, but not in Medicaid. The findings provide additional data to inform clinical recommendations for the treatment and postexposure prophylaxis of infections during pregnancy.</p>
<p><strong>Abstract:</strong> <a href="https://www.acpjournals.org/doi/10.7326/ANNALS-26-01647">https://www.acpjournals.org/doi/10.7326/ANNALS-26-01647</a></p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/11/doxycycline-use-in-early-pregnancy-associated-with-higher-risk-of-pregnancy-loss/">Doxycycline use in early pregnancy associated with higher risk of pregnancy loss</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Blood pressure meds may improve therapy for most common IBD</title>
		<link>https://pharmacyupdateonline.com/2026/11/blood-pressure-meds-may-improve-therapy-for-most-common-ibd/</link>
		
		<dc:creator><![CDATA[Charlie King]]></dc:creator>
		<pubDate>Thu, 12 Nov 2026 08:00:39 +0000</pubDate>
				<category><![CDATA[Gastroenterology]]></category>
		<category><![CDATA[Medicines & Therapeutics]]></category>
		<category><![CDATA[Pharmacology]]></category>
		<category><![CDATA[Practices & Services]]></category>
		<category><![CDATA[ACE inhibitors]]></category>
		<category><![CDATA[angiotensin receptor blockers]]></category>
		<category><![CDATA[hypertension]]></category>
		<category><![CDATA[inflammatory bowel disease]]></category>
		<category><![CDATA[ulcerative colitis]]></category>
		<category><![CDATA[Vedolizumab]]></category>
		<guid isPermaLink="false">https://pharmacyupdateonline.com/?p=23172</guid>

					<description><![CDATA[<p>A class of blood pressure medications may improve a widely used treatment for ulcerative colitis, the most common type of inflammatory bowel disease, suggests a new study, led [&#8230;]</p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/11/blood-pressure-meds-may-improve-therapy-for-most-common-ibd/">Blood pressure meds may improve therapy for most common IBD</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>A class of blood pressure medications may improve a widely used treatment for ulcerative colitis, the most common type of inflammatory bowel disease, suggests a new study, led by Northwestern Medicine and Kiel University in Germany, of thousands of patients with the disease.</p>
<p>The study found that those taking the blood pressure meds for hypertension alongside the ulcerative colitis drug vedolizumab (brand name Entyvio) were less likely to experience serious complications resulting in hospitalization and surgery to remove the colon.</p>
<p>The findings <a href="https://www.nature.com/articles/s41591-026-04741-8" target="_blank" rel="noopener">were published</a> on Nov. 9 in <em>Nature Medicine.</em></p>
<p>Ulcerative colitis, a chronic condition that causes inflammation and sores in the colon, affects over 1 million people in the U.S. and often begins in adolescence or young adulthood. Despite the emergence of advanced and expensive therapies, such as vedolizumab, most patients with ulcerative colitis do not achieve lasting remission with available treatments.</p>
<p>“You’re talking about teens or young adults who are suffering from uncontrollable diarrhea, bloody stool and an inability to function at school, work, or go out and have normal social interactions,” said study senior author <a href="https://www.feinberg.northwestern.edu/faculty-profiles/az/profile.html?xid=54556">Dr. Parambir Dulai</a>, associate professor of medicine in the division of gastroenterology and hepatology at Northwestern University Feinberg School of Medicine.</p>
<p>“And the psychosocial and physical impact of the disease is substantial, to the point where it may be on par with cancer in terms of the impact,” Dulai added. “Finding a new pathway where we have the potential to repurpose an inexpensive, generic, readily available medication could offer a tremendous reprieve for a lot of these young adults who are suffering on a daily basis.”</p>
<p><strong>How the study was conducted</strong></p>
<p>Dulai, Dr. Stefan Schreiber of Kiel University and their colleagues analyzed data from more than 1,300 patients enrolled in two clinical trials of vedolizumab for ulcerative colitis. By tracking how symptoms (stool frequency and rectal bleeding) changed over time in the trial participants, the scientists were able to identify different patterns of response to the drug.</p>
<p>Next, to understand the biology behind treatment resistance, the research team analyzed tissue biopsies and blood samples to measure gene and protein activity — and made two key discoveries. First, they found that poor response to vedolizumab was linked to a form of inflammation involving blood vessels in the colon. Second, they discovered that this inflammation was linked to a biological pathway that is already targeted by common blood pressure drugs known as ACE inhibitors and angiotensin receptor blockers, or ARBs.</p>
<p>Finally, to explore whether the blood pressure drugs could enhance the effectiveness of vedolizumab, the scientists analyzed healthcare data from nearly 9,000 ulcerative colitis patients who also had high blood pressure (hypertension). Among patients on vedolizumab, those taking ACE inhibitors or ARBs were less likely to be hospitalized or require surgery. Other blood pressure drug classes examined did not show the same association. The benefits were also specific to vedolizumab as patients taking ACE inhibitors or ARBs alongside other ulcerative colitis medications saw no difference.</p>
<p><strong>Next steps</strong></p>
<p>The study authors say clinical trials are now needed to confirm their findings and to understand how they might be applied to patients who have normal blood pressure.</p>
<p>“We don’t know yet if you can use anti-hypertensive medications in normal-tensive patients. People who have normal blood pressure, you don’t want to give them a medicine to drop their blood pressure,” said Dulai who also is a Northwestern Medicine physician and a member of the Center for Human Immunobiology at Feinberg. “There may be other ways to target that same pathway without the other effects that are present from blood pressure medications.”</p>
<p>“In other words, our study offers a rationale to start thinking about developing drugs specifically for this,” Dulai said.</p>
<p>Dulai said his team is also working on developing a diagnostic test based on the biological markers they discovered in those who didn’t respond to vedolizumab. Such a test could allow clinicians to identify, ahead of time, patients who are either likely to respond well to treatment or who would be better suited for alternatives.</p>
<p>That level of foresight could be crucial for “many patients who are starting these medications and are suffering from ongoing symptoms for months before they get any reprieve from finding a medication that works for them,” Dulai said.</p>
<p>Other Northwestern study co-authors are Cenfu Wei, Katherine Simpson, Zitong Lin, Isabella Peshek, Frida Chavez, Libeth Rosas and Alan Robinson.</p>
<p>The study is called “An ulcerative colitis taxonomy defined by individual patient-reported response trajectories.” It was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (grants R01DK135620 and U01DK134321), the European Union’s Innovative Medicines Initiative 2 (3TR and ImmUniverse projects), the German Research Foundation (DFG) and the German Federal Ministry of Education and Research (BMBF). Takeda, which manufactures vedolizumab, provided access to clinical trial data and supported the study.</p>
<div class="well">
<h4>Journal</h4>
<p>Nature Medicine</p>
</div>
<div class="well">
<h4>DOI</h4>
<p><a href="http://dx.doi.org/10.1038/s41591-026-04741-8" target="_blank" rel="noopener">10.1038/s41591-026-04741-8 <i class="fa fa-sign-out"></i></a></p>
</div>
<div class="well">
<h4>Article Title</h4>
<p>An ulcerative colitis taxonomy defined by individual patient-reported response trajectories</p>
</div>
<div class="well">
<h4>Article Publication Date</h4>
<p>9-Nov-2026</p>
</div>
<p>The post <a href="https://pharmacyupdateonline.com/2026/11/blood-pressure-meds-may-improve-therapy-for-most-common-ibd/">Blood pressure meds may improve therapy for most common IBD</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Vitamin K deficiency on the rise as more parents decline recommended shots for their newborns</title>
		<link>https://pharmacyupdateonline.com/2026/11/vitamin-k-deficiency-on-the-rise-as-more-parents-decline-recommended-shots-for-their-newborns/</link>
		
		<dc:creator><![CDATA[Charlie King]]></dc:creator>
		<pubDate>Wed, 11 Nov 2026 08:00:53 +0000</pubDate>
				<category><![CDATA[Paediatrics]]></category>
		<category><![CDATA[Practices & Services]]></category>
		<category><![CDATA[JAMA Pediatrics]]></category>
		<category><![CDATA[newborns]]></category>
		<category><![CDATA[paediatrics]]></category>
		<category><![CDATA[Virginia Commonwealth University]]></category>
		<category><![CDATA[vitamin K]]></category>
		<category><![CDATA[vitamin K deficiency bleeding]]></category>
		<guid isPermaLink="false">https://pharmacyupdateonline.com/?p=23155</guid>

					<description><![CDATA[<p>The American Academy of Pediatrics has recommended a single intramuscular dose of vitamin K for newborns since 1961; however, in the last decade parents have increasingly elected to [&#8230;]</p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/11/vitamin-k-deficiency-on-the-rise-as-more-parents-decline-recommended-shots-for-their-newborns/">Vitamin K deficiency on the rise as more parents decline recommended shots for their newborns</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The American Academy of Pediatrics has recommended a single intramuscular dose of vitamin K for newborns since 1961; however, in the last decade parents have increasingly elected to skip the shot.</p>
<p><a href="https://www.chrichmond.org/find-a-provider/profile/elizabeth-wolf" target="_blank" rel="noopener">Elizabeth Wolf</a>, M.D., MPH, a pediatrician at <a href="https://www.chrichmond.org/" target="_blank" rel="noopener">Children’s Hospital of Richmond at VCU</a> and an associate professor in the <a href="https://pediatrics.vcu.edu/" target="_blank" rel="noopener">Department of Pediatrics</a> at Virginia Commonwealth University School of Medicine, led a nationwide study to understand the change in vitamin K deficiency (VKD) and vitamin-K-deficient bleeding (VKDB). The results were <a href="https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2026.5794?guestAccessKey=96bb1e40-9080-4a62-ba58-d3fdf4e3e652" target="_blank" rel="noopener">published today in <em>JAMA Pediatrics</em></a><em>. </em></p>
<p>“We knew from prior studies that vitamin K refusal had been increasing in the U.S., and we wanted to learn if there were any real-life consequences of this trend,” Wolf said. “We found that the answer is undeniably yes, with the rates of VKD and VKDB multiplying over the course of our study.”</p>
<p><a href="https://familymedicine.vcu.edu/about/directories/steven-woolf-md-mph.html" target="_blank" rel="noopener">Steven Woolf</a>, M.D. director emeritus of the <a href="https://societyhealth.vcu.edu/#gsc.tab=0" target="_blank" rel="noopener">VCU Center on Society and Health</a> and professor in VCU School of Medicine’s <a href="https://familymedicine.vcu.edu/" target="_blank" rel="noopener">Department of Family Medicine</a>, was a co-author, along with Evan French, MS of VCU’s <a href="https://cctr.vcu.edu/" target="_blank" rel="noopener">C. Kenneth and Dianne Wright Center for Clinical and Translational Research</a>, and <a href="https://biostatistics.vcu.edu/people/students/niaki/" target="_blank" rel="noopener">Darya Shokouhi Niaki</a>, Pharm.D., of the VCU School of Public Health&#8217;s <a href="https://biostatistics.vcu.edu/" target="_blank" rel="noopener">Department of Biostatistics</a>.</p>
<p><strong>Vitamin K deficiency and associated bleeding in infants </strong></p>
<p>Vitamin K is essential for the activation of specialized proteins needed for normal blood clotting. Newborns have a deficiency of vitamin K because of inefficient transfer of vitamin K from the placenta, poor gastrointestinal absorption and low vitamin K content in breast milk.</p>
<p>Classical VKD, which occurs between 2 days and 1 week after birth, leads to bleeding of the umbilicus and bruising. Late VKD, occurring between ages 1 week and 6 months, carries a 30% to 60% risk of intracranial hemorrhage, which can result in seizures, permanent brain damage or death.</p>
<p>Despite this information, parents are increasingly refusing vitamin K injections at birth. <a href="https://jamanetwork.com/journals/jama/fullarticle/2842444" target="_blank" rel="noopener">Previous studies</a> found that between 2017 and 2024 the proportion of newborns not receiving intramuscular vitamin K rose from 2.9% to 5.2%.</p>
<p><strong>More than 11 million infants were studied with concerning results </strong></p>
<p>Using a large national database with deidentified electronic health record information from health systems across the U.S., researchers analyzed records from more than 11 million infants aged 0 to 6 months born at 35 weeks’ gestation or later who received care between 2017 and 2025.</p>
<p>Among the study’s findings:</p>
<ul>
<li>The percentage of newborns who received injectable vitamin K decreased from 97.7% to 95.0%.</li>
<li>The rate of VKD and VKDB increased by 216% and 347%, respectively.</li>
<li>Only 40% and about 19% of infants diagnosed with VKD and VKDB, respectively, received vitamin K shots.</li>
<li>Of those with VKD and VKDB, about 7% and 2%, respectively, also had a diagnosis of intracranial or intracerebral hemorrhage.</li>
</ul>
<p>Researchers caution that the simultaneous decrease in vitamin K injections and increase in diagnoses of VKD and VKDB between 2017 and 2025 does not prove causality. However, Wolf notes that other explanations are unlikely because behaviors and diseases that increase the risk for VKD remained constant or decreased during this period.</p>
<p><strong>Proper messaging to protect newborns in the years ahead </strong></p>
<p>Refusal of vitamin K has risen as mistrust in doctors and public health professionals has grown. Like childhood vaccines, the researchers say that vitamin K has been “a victim of its own success,” with many parents unaware that refusal of the shot can come with serious lifelong consequences.</p>
<p>More research is needed to identify the best ways to emphasize the seriousness of vitamin K deficiency and promote the use of vitamin K in newborns, Wolf says.</p>
<p>“We should continue to follow these trends moving forward since the rates of vitamin K deficiency and vitamin-K-deficient bleeding may continue to rise if vitamin K refusal keeps increasing. We need to better understand why parents are refusing vitamin K and what can be done to improve the uptake of this important medication,” Wolf said.</p>
<p>“Similar to the recent measles outbreaks, we are seeing the real-world implications of growing mistrust of doctors and public health professionals. We need clear messaging from all levels of public health about the benefits of vitamin K administration for newborns.”</p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/11/vitamin-k-deficiency-on-the-rise-as-more-parents-decline-recommended-shots-for-their-newborns/">Vitamin K deficiency on the rise as more parents decline recommended shots for their newborns</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Users engage with online health platforms despite privacy concerns</title>
		<link>https://pharmacyupdateonline.com/2026/11/users-engage-with-online-health-platforms-despite-privacy-concerns/</link>
		
		<dc:creator><![CDATA[Charlie King]]></dc:creator>
		<pubDate>Tue, 10 Nov 2026 08:00:15 +0000</pubDate>
				<category><![CDATA[Artificial intelligence]]></category>
		<category><![CDATA[Devices & Technology]]></category>
		<category><![CDATA[Pharmaceutical Technology]]></category>
		<category><![CDATA[Practices & Services]]></category>
		<category><![CDATA[Service Developments]]></category>
		<category><![CDATA[artificial intelligence]]></category>
		<category><![CDATA[Behavioral Sciences]]></category>
		<category><![CDATA[data privacy]]></category>
		<category><![CDATA[digital health]]></category>
		<category><![CDATA[mental health]]></category>
		<category><![CDATA[University of Southampton]]></category>
		<guid isPermaLink="false">https://pharmacyupdateonline.com/?p=23152</guid>

					<description><![CDATA[<p>People accessing health advice online can feel they have no choice but to put their trust in websites they visit despite having misgivings, suggests a University of Southampton [&#8230;]</p>
<p>The post <a href="https://pharmacyupdateonline.com/2026/11/users-engage-with-online-health-platforms-despite-privacy-concerns/">Users engage with online health platforms despite privacy concerns</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>People accessing health advice online can feel they have no choice but to put their trust in websites they visit despite having misgivings, suggests a University of Southampton study.</p>
<p>Researchers found users felt that convenience, ease of use, and crucially a lack of alternatives, outweigh their concerns about privacy and data security.</p>
<p>The team explored the feelings of people, both with and without lived experience of a mental health condition, towards internet-based technologies (IBTs) and sites that make use of artificial intelligence (AI), particularly in e-Health applications.</p>
<p>They found there was no clear difference in levels of trust between the two mental health status groups. However they revealed concern across both groups about trustworthiness and feelings of ‘digital resignation’ to features such as cookies.</p>
<p>Findings are published in the journal <em><a href="https://doi.org/10.3390/bs16111969">Behavioral Sciences</a>.</em></p>
<p>Lead author and psychologist Dr Emma Palmer-Cooper explains: “Our original concern was that people with serious mental health conditions, who can sometimes display more mistrust of others and of ‘cyber’ technologies, may be more likely to avoid IBTs designed to help them due to a level of paranoia or fear.</p>
<p>“We set up our study to explore this possibility, but our results showed this as less of an issue and that more general concerns about trust in digital technologies – common to both participant groups – were more prevalent.”</p>
<p>The researchers conducted qualitative semi-structured interviews over an eight month period in 2023 with 22 UK-based adult participants: eight with lived experience of a mental health condition and 14 without.</p>
<p>There was an overall consensus among participants that there is an imbalance between large companies and end-users, leading to trust issues. They linked trust in technology to trust in organisations, and had concerns about possible commercial influence.</p>
<p>Twelve out of the 22 declared a lack of trust in the internet generally, but continued to use IBTs and to abide by cookie settings they weren’t comfortable with. They justified this by citing convenience and time-saving benefits, along with acknowledging the trade-off between privacy and trust, versus user experience and greater functionality.</p>
<p>Some felt they had little choice but to accept cookies. As one participant put it: “<em>If you don’t accept, you can’t use the majority of online services.</em>”. Another stated: <em>“And I don’t trust it but as I said before, I have to in a way trust it in order to get to do what I want to do.”. </em>One described cookies as being designed to <em>“wear you down”</em>.</p>
<p>Throughout the interviews people spoke of wanting a balance between AI and human contact. They expressed anxiety about AI’s capabilities, in particular fear of its misuse and the prospect of AI replacing human employees. Two participants raised the issue of a need for greater regulation.</p>
<p>Professor Mark Weal of the School of Electronics and Computer Science at the University of Southampton says: “Our study shows there are clear ethical considerations for developers of online technologies and for the prescribers of eHealth interventions. It’s important online systems are developed responsibly to provide trust and genuine user autonomy.”</p>
<p>The researchers call on health professionals to understand data usage and privacy in the systems they recommend to patients and to balance support between human and eHealth provision.</p>
<ol>
<li>For interviews or further information contact Peter Franklin, Media and PR Manager, University of Southampton. +44 23 8059 3212 <a href="mailto:press@soton.ac.uk">press@soton.ac.uk</a></li>
<li>The paper “I Don’t Trust It, but I Have to Trust It”: Trust vs. Use of Online Technology Across the Mental Health Spectrum in the UK is published in the journal <em>Behavioral Sciences</em> DOI 10.3390/bs16111969 and can be viewed here: <a href="https://doi.org/10.3390/bs16111969">https://doi.org/10.3390/bs16111969</a></li>
<li>For more on the Psychology at the University of Southampton visit: <a href="https://www.southampton.ac.uk/study/subjects/psychology">https://www.southampton.ac.uk/study/subjects/psychology</a></li>
<li>The University of Southampton drives original thinking, turns knowledge into action and impact, and creates solutions to the world’s challenges. Our academics are leaders in their fields, forging links with high-profile international businesses and organisations, and inspiring a 25,000-strong community of exceptional students, from over 135 countries worldwide. Through our high-quality education, the University helps students on a journey of discovery to realise their potential and join our global network of over 300,000 alumni. <a href="http://www.southampton.ac.uk/">www.southampton.ac.uk</a></li>
</ol>
<p>The post <a href="https://pharmacyupdateonline.com/2026/11/users-engage-with-online-health-platforms-despite-privacy-concerns/">Users engage with online health platforms despite privacy concerns</a> appeared first on <a href="https://pharmacyupdateonline.com">Pharmacy Update Online</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
